Latest news with #MedicalInfoSystems
Yahoo
3 days ago
- Business
- Yahoo
P3 Health Partners Inc. (PIII) Reports Q2 Loss, Lags Revenue Estimates
P3 Health Partners Inc. (PIII) came out with a quarterly loss of $6.23 per share versus the Zacks Consensus Estimate of a loss of $3.29. This compares to a loss of $7.5 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -89.36%. A quarter ago, it was expected that this company would post a loss of $5 per share when it actually produced a loss of $6.28, delivering a surprise of -25.6%. Over the last four quarters, the company has not been able to surpass consensus EPS estimates. P3 Health Partners , which belongs to the Zacks Medical Info Systems industry, posted revenues of $355.79 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 2.03%. This compares to year-ago revenues of $379.16 million. The company has topped consensus revenue estimates just once over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. P3 Health Partners shares have lost about 36.9% since the beginning of the year versus the S&P 500's gain of 10%. What's Next for P3 Health Partners ? While P3 Health Partners has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for P3 Health Partners was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is -$5.04 on $342.9 million in revenues for the coming quarter and -$16.60 on $1.43 billion in revenues for the current fiscal year. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical Info Systems is currently in the top 36% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. Phreesia (PHR), another stock in the same industry, has yet to report results for the quarter ended July 2025. The results are expected to be released on September 4. This developer of health care software is expected to post quarterly loss of $0.07 per share in its upcoming report, which represents a year-over-year change of +77.4%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. Phreesia's revenues are expected to be $116.45 million, up 14% from the year-ago quarter. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report P3 Health Partners Inc. (PIII) : Free Stock Analysis Report Phreesia, Inc. (PHR) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
Yahoo
08-08-2025
- Business
- Yahoo
10x Genomics (TXG) Surpasses Q2 Earnings and Revenue Estimates
10x Genomics (TXG) came out with quarterly earnings of $0.28 per share, beating the Zacks Consensus Estimate of a loss of $0.35 per share. This compares to a loss of $0.32 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +180.00%. A quarter ago, it was expected that this life science technology company would post a loss of $0.45 per share when it actually produced a loss of $0.36, delivering a surprise of +20%. Over the last four quarters, the company has surpassed consensus EPS estimates three times. 10x Genomics, which belongs to the Zacks Medical Info Systems industry, posted revenues of $172.91 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 24.00%. This compares to year-ago revenues of $153.1 million. The company has topped consensus revenue estimates four times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. 10x Genomics shares have lost about 11.8% since the beginning of the year versus the S&P 500's gain of 7.9%. What's Next for 10x Genomics? While 10x Genomics has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for 10x Genomics was favorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #2 (Buy) for the stock. So, the shares are expected to outperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.25 on $144.82 million in revenues for the coming quarter and -$1.12 on $593.29 million in revenues for the current fiscal year. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical Info Systems is currently in the top 37% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. Another stock from the same industry, Tempus AI (TEM), has yet to report results for the quarter ended June 2025. The results are expected to be released on August 8. This health care technology company is expected to post quarterly loss of $0.23 per share in its upcoming report, which represents a year-over-year change of +63.5%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. Tempus AI's revenues are expected to be $299.32 million, up 80.4% from the year-ago quarter. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report 10x Genomics (TXG) : Free Stock Analysis Report Tempus AI, Inc. (TEM) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
Yahoo
18-07-2025
- Business
- Yahoo
Veeva Systems (VEEV) Stock Sinks As Market Gains: Here's Why
In the latest close session, Veeva Systems (VEEV) was down 2.13% at $276.46. This move lagged the S&P 500's daily gain of 0.54%. Elsewhere, the Dow gained 0.52%, while the tech-heavy Nasdaq added 0.74%. Heading into today, shares of the provider of cloud-based software services for the life sciences industry had gained 0.37% over the past month, outpacing the Medical sector's loss of 2.12% and lagging the S&P 500's gain of 4.2%. Investors will be eagerly watching for the performance of Veeva Systems in its upcoming earnings disclosure. It is anticipated that the company will report an EPS of $1.9, marking a 17.28% rise compared to the same quarter of the previous year. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $767.61 million, up 13.52% from the year-ago period. VEEV's full-year Zacks Consensus Estimates are calling for earnings of $7.64 per share and revenue of $3.1 billion. These results would represent year-over-year changes of +15.76% and +12.78%, respectively. Investors should also note any recent changes to analyst estimates for Veeva Systems. Recent revisions tend to reflect the latest near-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits. Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system. The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 0.6% higher. Right now, Veeva Systems possesses a Zacks Rank of #2 (Buy). From a valuation perspective, Veeva Systems is currently exchanging hands at a Forward P/E ratio of 36.95. This denotes a premium relative to the industry average Forward P/E of 28.78. It is also worth noting that VEEV currently has a PEG ratio of 1.59. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The Medical Info Systems was holding an average PEG ratio of 3.29 at yesterday's closing price. The Medical Info Systems industry is part of the Medical sector. This group has a Zacks Industry Rank of 83, putting it in the top 34% of all 250+ industries. The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Keep in mind to rely on to watch all these stock-impacting metrics, and more, in the succeeding trading sessions. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Veeva Systems Inc. (VEEV) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
